Cost-effectiveness and long-term outcomes of liver transplantation using hepatitis B core antibody-positive grafts with hepatitis B immunoglobulin prophylaxis in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Kyeong Deok | - |
dc.contributor.author | Lee, Ji Eun | - |
dc.contributor.author | Kim, Jong Man | - |
dc.contributor.author | Lee, Okjoo | - |
dc.contributor.author | Hwang, Na Young | - |
dc.contributor.author | Rhu, Jinsoo | - |
dc.contributor.author | Choi, Gyu-Seong | - |
dc.contributor.author | Kim, Kyunga | - |
dc.contributor.author | Joh, Jae-Won | - |
dc.date.accessioned | 2021-12-09T08:40:06Z | - |
dc.date.available | 2021-12-09T08:40:06Z | - |
dc.date.issued | 2021-10 | - |
dc.identifier.issn | 2287-2728 | - |
dc.identifier.issn | 2287-285X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/20122 | - |
dc.description.abstract | Background/Aims: Hepatitis B core antibody (anti-HBc)-positive donors are used as an extended donor pool, and current guidelines recommend the usage of nucleos(t)ide analogues (NAs) as prophylaxis for preventing de novo hepatitis B virus infection (DNH). We analyzed the long-term outcomes of a large cohort of liver transplantation (LT) patients receiving anti-HBc-positive grafts and evaluated the risk of DNH when hepatitis B immunoglobulin (HBIG) monotherapy was used as prophylaxis. We also compared the cost-effectiveness of HBIG and NAs. Methods: We retrospectively reviewed 457 patients with anti-HBc-positive grafts and 898 patients with anti-HBcnegative grafts who underwent LT between January 2001 and December 2018. We compared recipient characteristics according to the anti-HBc status of the donor, and compared the costs of using NAs for the rest of the patient's life and using HBIG to maintain hepatitis B surface antibody titers above 200 Ill/L. Results: The 1-, 5-, and 10-year patient survival rates were 87.7%, 73.5%, and 67.7%, respectively, in patients with antiHBc-positive grafts, and 88.5%, 77.4%, and 70.3%, respectively, in patients with anti-HBc-negative grafts (P=0.113). Among 457 recipients with anti-HBc-positive grafts, 117 (25.6%) were non-HBV recipients. The overall incidence of DNH was 0.9%. When using HBIG under insurance coverage, the cumulative cost was lower compared with using NA continuously without insurance coverage in Korea. Conclusions: Anti-HBc-positive grafts alone do not affect patient survival or graft survival. HBIG monoprophylaxis has good outcomes for preventing DNH, and the patient's long-term cost burden is low in Korea because of the national insurance system in this cohort. (Clin Mol Hepatol 2021;27:603-615) | - |
dc.format.extent | 13 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한간학회 | - |
dc.title | Cost-effectiveness and long-term outcomes of liver transplantation using hepatitis B core antibody-positive grafts with hepatitis B immunoglobulin prophylaxis in Korea | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.3350/cmh.2021.0137 | - |
dc.identifier.scopusid | 2-s2.0-85119981384 | - |
dc.identifier.wosid | 000706507200010 | - |
dc.identifier.bibliographicCitation | Clinical and Molecular Hepatology, v.27, no.4, pp 603 - 615 | - |
dc.citation.title | Clinical and Molecular Hepatology | - |
dc.citation.volume | 27 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 603 | - |
dc.citation.endPage | 615 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | DONORS | - |
dc.subject.keywordPlus | INFECTION | - |
dc.subject.keywordPlus | VIRUS | - |
dc.subject.keywordPlus | RECIPIENTS | - |
dc.subject.keywordAuthor | Liver transplantation | - |
dc.subject.keywordAuthor | Hepatitis B virus | - |
dc.subject.keywordAuthor | Hepatitis B core antibody | - |
dc.subject.keywordAuthor | De novo hepatitis B virus | - |
dc.subject.keywordAuthor | Hepatitis B immunoglobulin | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.